Zenas BioPharma Advances with Initial Public Offering Pricing

Author: Owen Jenkins Updated: 10-17-2025 07:06 PM

Zenas BioPharma Moves Forward with Initial Public Offering Pricing

Zenas BioPharma, Inc. (Nasdaq: ZBIO), an innovative biopharmaceutical company dedicated to groundbreaking immunology therapies, has just revealed the pricing details for its expanded initial public offering (IPO). The firm is offering 13,235,294 shares of its common stock at a price of $17.00 each, which will raise around $225.0 million in gross proceeds before any necessary expenses. Zenas remains focused on developing cutting-edge therapies for patients living with autoimmune diseases.

Details of the Offering

The shares are being exclusively offered by Zenas, with trading anticipated to begin on the Nasdaq Global Select Market. This is a pivotal step for the company as it strives to establish a strong position in the immunotherapy sector. The IPO is expected to finalize once all standard conditions are satisfied. Additionally, Zenas has granted the underwriters a 30-day option to purchase an extra 1,985,294 shares, which boosts the overall offering capacity.

Book-Running Managers

Leading financial institutions such as Morgan Stanley, Jefferies, Citigroup, and Guggenheim Securities will serve as joint book-running managers for this offering, underscoring a robust support system as Zenas transitions to a publicly traded company.

Pre-Offering Steps

Zenas has taken significant steps to prepare for this important milestone. It has filed registration statements with the U.S. Securities and Exchange Commission, which lays the groundwork for the shares being offered in the IPO. A final prospectus will provide investment details and will be available through the financial institutions involved.

About Zenas BioPharma

Zenas BioPharma is committed to reshaping treatment options for those affected by autoimmune diseases. With its leadership team’s vast expertise and a strategic approach to acquiring product candidates, the company is poised for success. Its primary candidate, obexelimab, is an innovative bifunctional monoclonal antibody designed to target both CD19 and Fc?RIIb. This mechanism aims to inhibit detrimental cell activities while safeguarding normal cellular functions.

Strategic Vision

Zenas envisions growing its portfolio through global acquisition and development efforts while maintaining a rigorous approach to identifying therapies that yield superior clinical outcomes. This positions Zenas as a promising entity in the biopharmaceutical industry, with the capability to change existing treatment paradigms.

Investor Relations

Investors looking for additional information can easily reach out to Zenas's investor relations team. Matthew Osborne serves as the primary contact for inquiries, committing to transparent communication and keeping the investment community informed.

Frequently Asked Questions

What is the price of Zenas BioPharma's IPO?

The IPO price is set at $17.00 per share, with the goal of raising approximately $225 million in gross proceeds.

Who are the underwriters for the IPO?

Morgan Stanley, Jefferies, Citigroup, and Guggenheim Securities are the joint book-running managers for this offering.

When is the expected trading start date for the shares?

The trading of Zenas' shares is expected to begin shortly after the offering closes, with the anticipated start date being September 13, 2024.

What is Zenas' lead product candidate?

Zenas' lead product candidate, obexelimab, is designed to target autoimmune diseases by interacting with critical B cell pathways.

How can I contact Zenas BioPharma for more information?

For inquiries, you can reach out to Matthew Osborne in the Investor Relations department or use the available communication channels.

About The Author

Hi there I'm 38-year-old author and financial consultant Owen Jenkins. Having worked in the financial sector for more than ten years, I am well-versed in the subtleties and complexity that mold our financial environment. Following a degree in finance, I worked in a number of financial institutions honing my abilities in market analysis, financial planning, and investment strategies.

My love is teaching others about investing and personal finance. My goal in writing many books and articles has been to demystify financial ideas and give readers the information they need to make wise financial decisions. I write with a direct, useful style that emphasizes doable suggestions for daily living.

Along with writing, I lead webinars and seminars where I impart knowledge on how to successfully negotiate the financial world. I also write for financial journals and show up as a guest expert on financial news programs a lot. Whether they are new to investing or want to improve their approach, my mission is to enable people to take charge of their financial futures.

Beyond work, I like to hike, play the guitar, and spend time with my family. I think that balance is crucial and want to encourage people to strike a balance between their financial aspirations and their hobbies. I want to help people succeed and achieve financial security through my work, so having a good influence.

Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.